News
-
Women of Bio21 - Louise Formby-MillerMeet Louise Formby-Miller, Senior Scientist, Rhythm Biosciences - animal friend, super-mum and Bikram yoga fan.
-
The Year That Made Me: Frances Separovic, 1996Listen to Professor Frances Separovic tell her story on Radio National's program: 'The year that made me': 1996
-
New Research Training Centre to lead the way for advanced chemical manufacturingThe Bio21 Institute hosted the launch of the new ARC Training Centre - Chemical Industries (ATCI) 21 September.
-
2018 Georgina Sweet Awards for Women in Quantitative Biomedical ScienceCongratulations to the 2018 winners; Cornelia Landersdorfer (Monash Institute of Pharmaceutical Sciences), Ana Traven (Monash Biomedicine Discovery Institute) and Aleksandra Filipovska (Harry Perkins Institute of Medical Research, UWA).
-
Using chemotherapy to fight malariaLeading malaria researcher Professor Leann Tilley and her team have uncovered the mechanism of how frontline antimalarial drug, artemisinin, works and are now working on a promising chemotherapy-based compound to treat patients.
-
Women of Bio21 - Kirsty TurnerMeet Kirsty Turner, Bio21's Research Support Services Manager, with responsibilities for oversight and support to the Institute’s platform technologies, research groups and industry tenants and most importantly her daughter Alyssa.
-
Bio21 researchers receive NHMRC Research FellowshipsCongratulations to Danny Hatters, Malcolm McConville and Jose Villadangos on being the recipients of National Health and Medical Research Council research fellowships.
-
Women of Bio21 - Jacqueline HeathMeet Jacqueline Heath, Early Career Researcher, Scholz Research Group, Reynolds Laboratory, Oral Health CRC, Bio21 Institute and Melbourne Dental School.
-
Dr Justine Mintern receives ARC Future FellowshipDr Mintern has received an ARC Future Fellow to investigate how material accesses different compartments inside cells, also known as trafficking.
-
Media Release: New anti-cancer drugs put cancers to sleep…permanentlyA member of the CRC program, St Vincent’s Institute and Bio21 Institute, University of Melbourne’s Professor Michael Parker and his team contributed to the structural biology of the target proteins KAT6A and KAT6B, as well as the corresponding selective inhibitors.
